このページの翻訳は実験的なもので、現在開発中です。お待ちしております

CXI Healthcare Technology Group バランスシートの健全性

財務の健全性基準チェック /66

CXI Healthcare Technology Groupの総株主資本は₩448.1B 、総負債は₩0.0で、負債比率は0%となります。総資産と総負債はそれぞれ₩450.8Bと₩2.7Bです。 CXI Healthcare Technology Groupの EBIT は₩16.6Bで、利息カバレッジ比率-75.3です。現金および短期投資は₩149.0Bです。

主要情報

負債資本比率

₩0

負債

インタレスト・カバレッジ・レシオ	-75.3x
現金	₩148.99b
エクイティ	₩448.05b
負債合計	₩2.72b
総資産	₩450.78b

財務の健全性に関する最新情報

更新なし

Recent updates

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Aug 05

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

May 30

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02

財務状況分析

短期負債: A900120の短期資産 ( ₩163.1B ) が短期負債 ( ₩2.6B ) を超えています。

長期負債: A900120の短期資産 ( ₩163.1B ) が長期負債 ( ₩99.9M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: A900120は負債がありません。

負債の削減: A900120負債比率が0.3%であった 5 年前と比べて負債がありません。

債務返済能力: A900120には負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: A900120には負債がないため、利息支払いの負担は問題になりません。

CXI Healthcare Technology Group バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

Investor sentiment improves as stock rises 28%

New major risk - Shareholder dilution

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

CKH Food & Health Limited announced that it has received KRW 7.432995165 billion in funding

New minor risk - Share price stability

Investor sentiment improves as stock rises 35%

Investor sentiment deteriorates as stock falls 16%

New major risk - Shareholder dilution

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

No independent directors

Investor sentiment improved over the past week

CKH Food & Health Limited announced that it has received KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited

CKH Food & Health Limited announced that it expects to receive KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited, and other investors

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99981 million.

Third quarter 2021 earnings released: ₩9.00 loss per share (vs ₩139 loss in 3Q 2020)

CKH Food & Health Limited announced that it has received KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it expects to receive KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it has received KRW 679.08 million in funding

CKH Food & Health Limited announced that it expects to receive KRW 679.08 million in funding

Second quarter 2021 earnings released: ₩17.00 loss per share (vs ₩133 loss in 2Q 2020)

New 90-day low: ₩405

First quarter 2021 earnings released: EPS ₩10.00

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩354

New 90-day high: ₩295

New 90-day high: ₩274

New 90-day low - ₩212

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /66